Developer docs
API playgroundTry for free, no card

Search company profiles

Twist Bioscience

Full company profile

uuid00007bf

Namestring
Twist Bioscience
Legal namestring
Twist Bioscience Corporation
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Twist Bioscience Corporation (NASDAQ: TWST), founded in 2013 and headquartered in South San Francisco, is a public synthetic biology company that manufactures synthetic DNA and related products on a proprietary semiconductor-based silicon platform. The core technology writes DNA directly onto silicon chips at densities up to 10,000x higher than conventional phosphoramidite chemistry, enabling massive parallel synthesis at lower cost. The product portfolio spans synthetic DNA products (clonal genes, gene fragments, gene pools, vectors, multiplexed gene fragments, oligo pools, variant libraries), next-generation sequencing (NGS) consumables (target enrichment panels, library preparation kits including TrueAmp, cfDNA and PCR-Free WGS kits, synthetic viral controls), and antibody discovery services that incorporate in vitro and in vivo capabilities (via the Abveris subsidiary), antibody engineering, and the newly licensed B-Body bispecific antibody platform.

The company monetizes through one-time product sales of synthetic DNA and NGS consumables priced via quote-based enterprise pricing (with a 30% promotional discount for new Multiplexed Gene Fragments customers) plus professional-service fees for antibody discovery, AI-enabled drug discovery CRO work, and biopharma partnerships. Go-to-market combines direct enterprise field sales to biopharma and academic customers, a self-serve e-commerce platform (ecommerce.twistdna.com), programmatic ordering via the Twist API (TAPI), and embedded integrations with platforms such as Benchling, Volta Labs Callisto, and AWS Amazon Bio Discovery. Customer segments are diverse: biopharmaceutical companies (Bayer, Broad Institute, Voyager Therapeutics, Memorial Sloan Kettering) for antibody and nucleic acid therapeutics, academic and research institutions (UC Berkeley, University of Missouri) for genomics and synthetic biology, agricultural biotechnology firms (Phytoform Labs) for crop engineering, and diagnostics/clinical research organizations for liquid biopsy and MRD applications.

Twist reported Q2 FY2026 revenue of $110.7M (+19.3% YoY), its 13th consecutive quarter of sequential growth, with FY2026 guidance of $442–447M (17–19% projected growth), a Q2 gross margin of 51.6% trending toward 55%+, $172M in net cash with no debt, and a path to Q4 adjusted EBITDA breakeven. Recent strategic moves include selection as the wet-lab partner for AWS's Amazon Bio Discovery platform, launch of Complex Genes for AI-generated sequences, the Invenra B-Body bispecific license, and ecosystem integrations with Benchling, LenioBio, and Volta Labs, all oriented toward capturing share of the projected $12B long-term addressable market by 2030.

Short descriptiontext

Twist Bioscience is a public synthetic biology company that uses a proprietary semiconductor-based silicon platform to manufacture synthetic DNA, NGS consumables, and antibody discovery services for biopharmaceutical, academic, agricultural biotechnology, and diagnostics customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic DNA manufacturing, gene synthesis services, oligonucleotide pool production, next-generation sequencing panels, antibody discovery services
Industry3 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Synthetic Biology / DNA Synthesis
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Synthetic DNA Products
TypeOne Time License
Description

Sale of synthetic genes, gene fragments, oligo pools, and variant libraries for research applications. Products include clonal genes, gene pools, vectors, multiplexed gene fragments, and express genes for various downstream applications including therapeutics development and agricultural biotechnology

fool.com
2NGS Products and Services
TypeOne Time License
Description

Next-generation sequencing consumables including target enrichment panels, library preparation kits, synthetic controls, and RNA sequencing solutions. Includes fixed content panels (exome, methylation, viral), custom panels, and automation solutions

seekingalpha.com
3Biopharma Services
TypeProfessional Services
Description

Antibody discovery and development services including in vitro and in vivo antibody discovery, antibody engineering and optimization, production, and characterization. Also includes bispecific antibody platform services through Invenra partnership

openpr.com
4AI-Enabled Drug Discovery
TypeProfessional Services
Description

Wet-lab partnership services for AI-driven drug discovery workflows, serving as CRO partner for platforms like AWS Amazon Bio Discovery, providing DNA synthesis and testing services for computational biology applications

seekingalpha.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
130% new customer discount on Multiplexed Gene Fragments
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Special promotional pricing for new customers on initial orders of Multiplexed Gene Fragments product

twistbioscience.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Twist Bioscience manufactures synthetic DNA products (genes, gene fragments, oligo pools, variant libraries) using a proprietary semiconductor-based silicon platform, and supplies next-generation sequencing consumables (target enrichment panels, library preparation kits, synthetic controls). The company also provides antibody discovery and biopharma services, including in vitro and in vivo antibody screening, bispecific antibody development through the licensed B-Body platform, and wet-lab services supporting AI-driven drug discovery workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • DNA synthesis density up to 10,000x higher than conventional methods
+4 more records
Product overview1 text field

Twist Bioscience is a synthetic biology company offering a semiconductor-based DNA synthesis platform. The product portfolio centers on DNA synthesis products (Genes including Clonal Genes, Gene Fragments, Complex Genes, Gene Pools, Vectors; and Oligo Pools) and Next-Generation Sequencing (NGS) solutions including target enrichment panels, library preparation kits (TrueAmp, cfDNA Library Prep), and synthetic controls. The company also provides Antibody Discovery Services including in vitro/in vivo discovery, the B-Body bispecific antibody platform, and Variant Libraries (combinatorial, SOLD, site saturation). These products are complemented by an API (TAPI) for programmatic access. The platform serves biopharma, academic research, and agricultural biotechnology customers with AI-enabled drug discovery capabilities through partnerships with AWS, Benchling, and LenioBio.

Product and service13 records
1Genes
CategorySynthetic DNA Products
Description

Twist Bioscience's core gene synthesis product enabling researchers to order synthetic DNA genes for protein expression, metabolic engineering, and pathway construction. Includes clonal genes, gene fragments, gene pools, vectors, express genes, and multiplexed gene fragments.

2Clonal Genes
CategorySynthetic DNA Products
Description

Synthetically manufactured genes delivered as single bacterial colonies with guaranteed sequence accuracy, ideal for protein expression and downstream applications requiring clonal DNA.

3Complex Genes
CategorySynthetic DNA Products
Description

Early access product enabling synthesis of complex DNA sequences up to 7,000 base pairs with approximately 99.5% acceptance rate. Targets previously difficult-to-manufacture sequences including tandem repeats, inverted repeats, and high/low GC content regions for AI-enabled drug discovery and nucleic acid therapeutics.

4Oligo Pools
CategorySynthetic DNA Products
Description

High-throughput oligonucleotide pool synthesis enabling CRISPR screens, gene assembly, and other applications requiring large numbers of oligos. Includes cloned oligo pools and standard oligo pools.

5Variant Libraries
CategorySynthetic DNA Products
Description

Comprehensive variant library products including combinatorial variant libraries, spread-out low diversity (SOLD) libraries, site saturation libraries, and TCR libraries for protein engineering and functional genomics applications.

6NGS Target Enrichment Solutions
CategoryNext-Generation Sequencing
Description

Comprehensive next-generation sequencing solutions including custom panels, fixed content panels, target enrichment panels, and library preparation kits enabling precise sequencing across various applications such as cancer research, liquid biopsy, and infectious disease surveillance.

7TrueAmp Library Preparation Kit
CategoryNext-Generation Sequencing
Description

NGS library preparation kit enabling high uniformity across GC-rich, AT-rich, and repeat-dense regions for next-generation sequencing workflows.

8cfDNA Library Prep Kit with TrueAmp Polymerase Mix
CategoryNext-Generation Sequencing
Description

Cell-free DNA library preparation kit for liquid biopsy and cancer research applications, enabling sensitive detection of circulating tumor DNA.

9MRD Express
CategoryNext-Generation Sequencing
Description

Minimal residual disease detection panel enabling sensitive tracking of cancer recurrence through liquid biopsy testing.

10Synthetic Controls
CategoryNext-Generation Sequencing
Description

Synthetic RNA and DNA standards for assay development including SARS-CoV-2 controls, monkeypox virus controls, and respiratory virus controls for quality control and validation.

11Antibody Discovery Services
CategoryBiopharma Services
Description

Full-service antibody discovery and development offerings including in vitro discovery, in vivo discovery (via Abveris), antibody engineering and optimization, production and characterization, and bispecific antibodies through the B-Body platform.

12B-Body Bispecific Antibody Platform
CategoryBiopharma Services
Description

Licensed bispecific antibody discovery platform enabling co-exclusive development and marketing of bispecific therapeutics, with 20% royalty on clinical trial revenue.

13Twist API (TAPI)
CategorySoftware / API
Description

Programmatic API enabling developers to integrate DNA synthesis ordering, gene ordering, and other lab services directly into their workflows and systems, supporting automated order placement and integration with platforms like Benchling.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-01
Description

Launch of Twist Fast Hybridization App on Volta Labs Callisto Sample Prep System, completing the full Twist hybrid capture portfolio on the platform. Automated workflow reduces hybridization from overnight to same-day processing while maintaining equivalent sequencing performance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-08
Description

Strategic partnership integrating LenioBio's ALiCE cell-free protein expression platform with Twist's DNA manufacturing capabilities to accelerate AI-driven protein and antibody design services. ALiCE enables production of full-length, folded, functional proteins within 24 hours, compressing design-build-test cycles for AI workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-01
Description

One-Click Ordering integration enabling scientists to design experiments, submit orders, and receive structured results directly within Benchling platform. Integration creates continuous feedback loop tying orders to experimental context for downstream analysis and model training.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

AWS selected Twist Bioscience as wet-lab partner for Amazon Bio Discovery, an AI-powered drug discovery platform. Twist provides DNA synthesis and wet-lab testing services for computationally designed antibody candidates, enabling rapid lab-in-the-loop experimentation cycles for biopharma researchers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

CRO partner for Amazon Bio Discovery platform providing synthetic DNA, protein expression, biophysical characterization, and developability assay services for AI-driven drug discovery workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-01
Description

Co-exclusive licensing agreement for B-Body bispecific antibody platform, expanding Twist's biologics discovery services. Twist paid $5 million in cash and approximately $15 million in Twist common stock, with Invenra receiving 20% royalty on license revenue from customers entering human clinical trials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript is a direct competitor in synthetic gene synthesis, gene fragments, oligo pools, and protein/antibody services, with comparable offerings across Twist's core product lines.

TypeDirect peer
Description

IDT is a leading competitor in synthetic DNA, oligos, and NGS library preparation, serving similar biopharma and academic customers with overlapping product portfolios.

TypeDirect peer
Description

Eurofins Genomics offers gene synthesis, oligo synthesis, and NGS services, directly competing with Twist in synthetic DNA and sequencing consumables.

TypeDirect peer
Description

Synthego specializes in synthetic biology, CRISPR reagents, and gene synthesis, competing with Twist's oligo pools and gene fragment products for research and therapeutic customers.

5DNA Script
TypeEmerging player
Description

DNA Script is an emerging competitor using enzymatic DNA synthesis, an alternative to Twist's silicon-based phosphoramidite platform, targeting the same synthetic DNA market.

TypeEmerging player
Description

AbCellera is an AI-driven antibody discovery company overlapping with Twist's biopharma services segment, particularly the in vivo and in vitro antibody discovery offerings.

TypeEmerging player
Description

Absci is a direct AI drug discovery partner of Twist and also a competitor in generative AI antibody design, sharing the AI biology infrastructure narrative.

TypeBroad incumbent
Description

Ginkgo Bioworks is a synthetic biology services platform that is both a CRO partner of Twist on Amazon Bio Discovery and a broader competitor in cell engineering and biologics services.

TypeEmerging player
Description

Codexis is a protein engineering platform company using directed evolution, adjacent to Twist's variant library and protein engineering offerings for therapeutics applications.

TypeBroad incumbent
Description

10x Genomics is a broader incumbent in genomics tools and NGS workflows, competing with Twist in the sequencing consumables and target enrichment space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Twist Bioscience

Synthetic Biology / DNA Synthesistwistbioscience.com

Twist Bioscience is a public synthetic biology company that uses a proprietary semiconductor-based silicon platform to manufacture synthetic DNA, NGS consumables, and antibody discovery services for biopharmaceutical, academic, agricultural biotechnology, and diagnostics customers.

What Twist Bioscience does

Twist Bioscience Corporation (NASDAQ: TWST), founded in 2013 and headquartered in South San Francisco, is a public synthetic biology company that manufactures synthetic DNA and related products on a proprietary semiconductor-based silicon platform. The core technology writes DNA directly onto silicon chips at densities up to 10,000x higher than conventional phosphoramidite chemistry, enabling massive parallel synthesis at lower cost. The product portfolio spans synthetic DNA products (clonal genes, gene fragments, gene pools, vectors, multiplexed gene fragments, oligo pools, variant libraries), next-generation sequencing (NGS) consumables (target enrichment panels, library preparation kits including TrueAmp, cfDNA and PCR-Free WGS kits, synthetic viral controls), and antibody discovery services that incorporate in vitro and in vivo capabilities (via the Abveris subsidiary), antibody engineering, and the newly licensed B-Body bispecific antibody platform.

The company monetizes through one-time product sales of synthetic DNA and NGS consumables priced via quote-based enterprise pricing (with a 30% promotional discount for new Multiplexed Gene Fragments customers) plus professional-service fees for antibody discovery, AI-enabled drug discovery CRO work, and biopharma partnerships. Go-to-market combines direct enterprise field sales to biopharma and academic customers, a self-serve e-commerce platform (ecommerce.twistdna.com), programmatic ordering via the Twist API (TAPI), and embedded integrations with platforms such as Benchling, Volta Labs Callisto, and AWS Amazon Bio Discovery. Customer segments are diverse: biopharmaceutical companies (Bayer, Broad Institute, Voyager Therapeutics, Memorial Sloan Kettering) for antibody and nucleic acid therapeutics, academic and research institutions (UC Berkeley, University of Missouri) for genomics and synthetic biology, agricultural biotechnology firms (Phytoform Labs) for crop engineering, and diagnostics/clinical research organizations for liquid biopsy and MRD applications.

Twist reported Q2 FY2026 revenue of $110.7M (+19.3% YoY), its 13th consecutive quarter of sequential growth, with FY2026 guidance of $442–447M (17–19% projected growth), a Q2 gross margin of 51.6% trending toward 55%+, $172M in net cash with no debt, and a path to Q4 adjusted EBITDA breakeven. Recent strategic moves include selection as the wet-lab partner for AWS's Amazon Bio Discovery platform, launch of Complex Genes for AI-generated sequences, the Invenra B-Body bispecific license, and ecosystem integrations with Benchling, LenioBio, and Volta Labs, all oriented toward capturing share of the projected $12B long-term addressable market by 2030.

Twist Bioscience firmographics

Firmographics
Name
Twist Bioscience
Legal name
Twist Bioscience Corporation
Website
https://twistbioscience.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Twist Bioscience is a public synthetic biology company that uses a proprietary semiconductor-based silicon platform to manufacture synthetic DNA, NGS consumables, and antibody discovery services for biopharmaceutical, academic, agricultural biotechnology, and diagnostics customers.
Ownership category
akta.pro rank

Twist Bioscience industry classification

Industry
Product category
Synthetic Biology / DNA Synthesis
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Synthetic DNA manufacturing
  • Gene synthesis services
  • Oligonucleotide pool production
  • Next-generation sequencing panels
  • Antibody discovery services

Where Twist Bioscience is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Twist Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Synthetic DNA Products: Sale of synthetic genes, gene fragments, oligo pools, and variant libraries for research applications. Products include clonal genes, gene pools, vectors, multiplexed gene fragments, and express genes for various downstream applications including therapeutics development and agricultural biotechnology
  2. NGS Products and Services: Next-generation sequencing consumables including target enrichment panels, library preparation kits, synthetic controls, and RNA sequencing solutions. Includes fixed content panels (exome, methylation, viral), custom panels, and automation solutions
  3. Biopharma Services: Antibody discovery and development services including in vitro and in vivo antibody discovery, antibody engineering and optimization, production, and characterization. Also includes bispecific antibody platform services through Invenra partnership
  4. AI-Enabled Drug Discovery: Wet-lab partnership services for AI-driven drug discovery workflows, serving as CRO partner for platforms like AWS Amazon Bio Discovery, providing DNA synthesis and testing services for computational biology applications

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-go30% new customer discount on Multiplexed Gene Fragments

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Twist Bioscience product offering

Product offering

Core offering

Twist Bioscience manufactures synthetic DNA products (genes, gene fragments, oligo pools, variant libraries) using a proprietary semiconductor-based silicon platform, and supplies next-generation sequencing consumables (target enrichment panels, library preparation kits, synthetic controls). The company also provides antibody discovery and biopharma services, including in vitro and in vivo antibody screening, bispecific antibody development through the licensed B-Body platform, and wet-lab services supporting AI-driven drug discovery workflows.

Product overview

Twist Bioscience is a synthetic biology company offering a semiconductor-based DNA synthesis platform. The product portfolio centers on DNA synthesis products (Genes including Clonal Genes, Gene Fragments, Complex Genes, Gene Pools, Vectors; and Oligo Pools) and Next-Generation Sequencing (NGS) solutions including target enrichment panels, library preparation kits (TrueAmp, cfDNA Library Prep), and synthetic controls. The company also provides Antibody Discovery Services including in vitro/in vivo discovery, the B-Body bispecific antibody platform, and Variant Libraries (combinatorial, SOLD, site saturation). These products are complemented by an API (TAPI) for programmatic access. The platform serves biopharma, academic research, and agricultural biotechnology customers with AI-enabled drug discovery capabilities through partnerships with AWS, Benchling, and LenioBio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genes Twist Bioscience's core gene synthesis product enabling researchers to order synthetic DNA genes for protein expression, metabolic engineering, and pathway construction. Includes clonal genes, gene fragments, gene pools, vectors, express genes, and multiplexed gene fragments.
  • Clonal Genes Synthetically manufactured genes delivered as single bacterial colonies with guaranteed sequence accuracy, ideal for protein expression and downstream applications requiring clonal DNA.
  • Complex Genes Early access product enabling synthesis of complex DNA sequences up to 7,000 base pairs with approximately 99.5% acceptance rate. Targets previously difficult-to-manufacture sequences including tandem repeats, inverted repeats, and high/low GC content regions for AI-enabled drug discovery and nucleic acid therapeutics.
  • Oligo Pools High-throughput oligonucleotide pool synthesis enabling CRISPR screens, gene assembly, and other applications requiring large numbers of oligos. Includes cloned oligo pools and standard oligo pools.
  • Variant Libraries Comprehensive variant library products including combinatorial variant libraries, spread-out low diversity (SOLD) libraries, site saturation libraries, and TCR libraries for protein engineering and functional genomics applications.
  • NGS Target Enrichment Solutions Comprehensive next-generation sequencing solutions including custom panels, fixed content panels, target enrichment panels, and library preparation kits enabling precise sequencing across various applications such as cancer research, liquid biopsy, and infectious disease surveillance.
  • TrueAmp Library Preparation Kit NGS library preparation kit enabling high uniformity across GC-rich, AT-rich, and repeat-dense regions for next-generation sequencing workflows.
  • cfDNA Library Prep Kit with TrueAmp Polymerase Mix Cell-free DNA library preparation kit for liquid biopsy and cancer research applications, enabling sensitive detection of circulating tumor DNA.
  • MRD Express Minimal residual disease detection panel enabling sensitive tracking of cancer recurrence through liquid biopsy testing.
  • Synthetic Controls Synthetic RNA and DNA standards for assay development including SARS-CoV-2 controls, monkeypox virus controls, and respiratory virus controls for quality control and validation.
  • Antibody Discovery Services Full-service antibody discovery and development offerings including in vitro discovery, in vivo discovery (via Abveris), antibody engineering and optimization, production and characterization, and bispecific antibodies through the B-Body platform.
  • B-Body Bispecific Antibody Platform Licensed bispecific antibody discovery platform enabling co-exclusive development and marketing of bispecific therapeutics, with 20% royalty on clinical trial revenue.
  • Twist API (TAPI) Programmatic API enabling developers to integrate DNA synthesis ordering, gene ordering, and other lab services directly into their workflows and systems, supporting automated order placement and integration with platforms like Benchling.

Quantifiable outcome

  • DNA synthesis density up to 10,000x higher than conventional methods
  • +4 more outcomes

Companies that use Twist Bioscience

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Twist Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature4 records

Twist Bioscience partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Volta LabscoreTechnology or Integration · 1 June 2026Launch of Twist Fast Hybridization App on Volta Labs Callisto Sample Prep System, completing the full Twist hybrid capture portfolio on the platform. Automated workflow reduces hybridization from overnight to same-day processing while maintaining equivalent sequencing performance.
  • LenioBiocoreStrategic or Co-development Partner · 8 May 2026Strategic partnership integrating LenioBio's ALiCE cell-free protein expression platform with Twist's DNA manufacturing capabilities to accelerate AI-driven protein and antibody design services. ALiCE enables production of full-length, folded, functional proteins within 24 hours, compressing design-build-test cycles for AI workflows.
  • BenchlingcoreTechnology or Integration · 1 May 2026One-Click Ordering integration enabling scientists to design experiments, submit orders, and receive structured results directly within Benchling platform. Integration creates continuous feedback loop tying orders to experimental context for downstream analysis and model training.
  • Amazon Web Services (AWS)coreTechnology or Integration · 1 April 2026AWS selected Twist Bioscience as wet-lab partner for Amazon Bio Discovery, an AI-powered drug discovery platform. Twist provides DNA synthesis and wet-lab testing services for computationally designed antibody candidates, enabling rapid lab-in-the-loop experimentation cycles for biopharma researchers.
  • Ginkgo BioworkscoreTechnology or Integration · 1 April 2026CRO partner for Amazon Bio Discovery platform providing synthetic DNA, protein expression, biophysical characterization, and developability assay services for AI-driven drug discovery workflows.
  • InvenracoreTechnology or Integration · 1 February 2026Co-exclusive licensing agreement for B-Body bispecific antibody platform, expanding Twist's biologics discovery services. Twist paid $5 million in cash and approximately $15 million in Twist common stock, with Invenra receiving 20% royalty on license revenue from customers entering human clinical trials.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Twist Bioscience competitors and assessment

Company assessment

Direct peers

  • GenScript: GenScript is a direct competitor in synthetic gene synthesis, gene fragments, oligo pools, and protein/antibody services, with comparable offerings across Twist's core product lines.
  • Integrated DNA Technologies (IDT, Danaher): IDT is a leading competitor in synthetic DNA, oligos, and NGS library preparation, serving similar biopharma and academic customers with overlapping product portfolios.
  • Eurofins Genomics: Eurofins Genomics offers gene synthesis, oligo synthesis, and NGS services, directly competing with Twist in synthetic DNA and sequencing consumables.
  • Synthego: Synthego specializes in synthetic biology, CRISPR reagents, and gene synthesis, competing with Twist's oligo pools and gene fragment products for research and therapeutic customers.

Emerging players

  • DNA Script: DNA Script is an emerging competitor using enzymatic DNA synthesis, an alternative to Twist's silicon-based phosphoramidite platform, targeting the same synthetic DNA market.
  • AbCellera Biologics: AbCellera is an AI-driven antibody discovery company overlapping with Twist's biopharma services segment, particularly the in vivo and in vitro antibody discovery offerings.
  • Absci: Absci is a direct AI drug discovery partner of Twist and also a competitor in generative AI antibody design, sharing the AI biology infrastructure narrative.
  • Codexis: Codexis is a protein engineering platform company using directed evolution, adjacent to Twist's variant library and protein engineering offerings for therapeutics applications.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a synthetic biology services platform that is both a CRO partner of Twist on Amazon Bio Discovery and a broader competitor in cell engineering and biologics services.
  • 10x Genomics: 10x Genomics is a broader incumbent in genomics tools and NGS workflows, competing with Twist in the sequencing consumables and target enrichment space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Twist Bioscience social profiles

Digital presence

Twist Bioscience compliance and trust

Trust signal

Compliance1 record

Twist Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Twist Bioscience leadership team

Management profile

Number of profiles

Profiles3 records

Twist Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Twist Bioscience funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Twist Bioscience M&A and investment

M&A and investment

M&A3 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Twist Bioscience

What does Twist Bioscience do?

Twist Bioscience manufactures synthetic DNA products (genes, gene fragments, oligo pools, variant libraries) using a proprietary semiconductor-based silicon platform, and supplies next-generation sequencing consumables (target enrichment panels, library preparation kits, synthetic controls). The company also provides antibody discovery and biopharma services, including in vitro and in vivo antibody screening, bispecific antibody development through the licensed B-Body platform, and wet-lab services supporting AI-driven drug discovery workflows.

Is Twist Bioscience a public or private company?

Twist Bioscience is a public company. It is classified as public and is currently operating.

When was Twist Bioscience founded?

Twist Bioscience was founded in 2013. It employs 1,001 to 5,000 people.

Where is Twist Bioscience based?

Twist Bioscience is headquartered in South San Francisco, United States, in the North America region.

How does Twist Bioscience make money?

Four revenue lines are on record. Synthetic DNA Products are the primary driver. The others are NGS Products and Services, biopharma Services and AI-Enabled Drug Discovery.

Who are Twist Bioscience's main competitors?

Direct peers on record are GenScript, Integrated DNA Technologies (IDT, Danaher), Eurofins Genomics and Synthego. Emerging players are DNA Script, AbCellera Biologics, Absci and Codexis. Broad incumbents are Ginkgo Bioworks and 10x Genomics.

Does Twist Bioscience have an API?

Yes. Twist Bioscience offers an API called TAPI (Twist API) for programmatic access to ordering and managing synthetic DNA products. The API enables developers to integrate DNA synthesis ordering, gene ordering, and other lab services directly into their workflows and systems. Developer documentation is at www.twistbioscience.com/tapi.

What industry is Twist Bioscience in?

Twist Bioscience's product category is Synthetic Biology / DNA Synthesis. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBarclays maintains Twist Bioscience at Overweight, lowers price target to $130 from $215Barclays maintained its Overweight rating on Twist Bioscience but cut its price target to $130 from $215, a 39.5% decrease. The new target implies a 16.5% upside from the Nov 13 close of $111.60. Recent analyst price targets range from $135 to $175.Simply Wall StTwist Bioscience (TWST) Stock May Look Rich As Sales Face A High BarTwist Bioscience's share price has surged 364.8% over three years, putting pressure on its sales to justify the valuation. The stock trades at a P/S of 15.2x, above the biotech industry average of 9.8x and peer group of 14.1x, suggesting it may be overvalued. The next move depends on whether its revenue quality and growth opportunity justify the premium.TradingViewLeerink Partners maintains Twist Bioscience at Outperform, lowers price target to $175 from $190Leerink Partners maintained its Outperform rating on Twist Bioscience and cut its price target to $175 from $190. The new target implies a 53.2% upside from the Nov 12 close of $114.22. Recent analyst price targets range from $135 to $150.Simply Wall StThe Bet Twist Bioscience Holders Made Before A 282% JumpTwist Bioscience shares rose 282% over the past year, trading at $114 after a year of losses. The company reported record Q2 and Q3 revenue of $110.7M and $118.4M, but still posted net losses of $44M and $35.1M. Analysts see a fair value below current price, citing ongoing GAAP net loss risk.TradingViewBaird maintains Twist Bioscience at Outperform, lowers price target to $135 from $187Baird maintained Twist Bioscience at Outperform and lowered its price target to $135 from $187, a 27.8% decrease. The target implies an upside of 18.2% from the Nov 12 close of $114.22.Investing.comCanaccord cuts Twist Bioscience stock price target on lower revenue outlookCanaccord lowered its price target on Twist Bioscience to $150 from $205, keeping a Buy rating. The cut reflects lower revenue estimates in its 10-year DCF model, even though Twist's Q4 revenue beat expectations at $126.6 million. The company expects positive EBITDA in fiscal 2027 and increased capex in 2027-2028.The Motley FoolTwist Bioscience: 3 Key Takeaways for Long-Term InvestorsTwist Bioscience reported Q4 fiscal 2026 revenue of $126.6 million, up 28% year over year, and achieved positive adjusted EBITDA. AI drug discovery revenue grew 175% to $59.1 million, and the company expects fiscal 2027 revenue of $550–560 million.The Motley FoolTwist Bioscience (TWST) Q4 2026 Earnings Call TranscriptTwist Bioscience reported Q4 2026 revenue of $126.6 million, up 28% year-over-year, and positive adjusted EBITDA of $2.2 million for the first time. Full-year revenue reached $459.4 million, exceeding guidance, with fiscal 2027 revenue guidance of $550–560 million. The company plans $150 million in capital expenditures over fiscal 2027–2028 to expand capacity.The Motley FoolTwist Bioscience (TWST) Q4 2026 Earnings Call TranscriptTwist Bioscience reported Q4 2026 revenue of $126.6 million, up 28% year-over-year, and positive adjusted EBITDA of $2.2 million for the first time. Full-year revenue reached $459.4 million, exceeding guidance by over $30 million, with fiscal 2027 revenue guidance of $550–560 million.Seeking AlphaTwist Bioscience outlines FY2027 revenue of $550M-$560M while staying adjusted EBITDA positive amid AI drug discovery expansionTwist Bioscience guided FY2027 revenue to $550M-$560M and reported positive adjusted EBITDA in Q4 fiscal 2026. CEO Dr. Emily Leproust said the company accelerated top-line growth and expanded capabilities for AI drug discovery opportunities.